. Author manuscript; available in PMC: 2016 Apr 13.

Published in final edited form as: Cancer Cell. 2015 Apr 6;27(4):450–461. doi: 10.1016/j.ccell.2015.03.001

Table 1.

Drugs in clinical development that block PD-1 or PD-L1

Target	Drug name	Other names	Source	Isotype and characteristics	Clinical testing phase
PD-1	MEDI0680	AMP-514	MedImmune/ AstraZeneca	Information not available	Phase I
	Nivolumab	Opdivo; BMS-936558; MDX-1106; ONO-4538	Bristol-Myers Squibb; Ono Pharmaceuticals	Fully human IgG4^a	Approved, treatment-refractory unresectable melanoma (Japan, US) and squamous NSCLC (US)
	Pembrolizumab	Keytruda; MK-3475; lambrolizumab	Merck	Humanized IgG4	Approved, treatment-refractory unresectable melanoma (US)
	Pidilizumab	CT-011	CureTech	Humanized IgG1	Phase I–II
PD-L1	BMS-936559	MDX-1105	Bristol-Myers Squibb	Fully human IgG4^a	Phase I
	MEDI4736	none	MedImmune/AstraZeneca	Fc-modified human IgG1^b	Phase I–III
	MPDL3280A	RG7446	Genentech/ Roche	Fc-modified human IgG1^b	Phase I–III
	MSB0010718C	none	EMD Serono	Fully human IgG1^a	Phase I–II

^(a)

Fully human mAbs were produced in genetically engineered mice.

^(b)

Fc-modified mAbs were engineered to abrogate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).